USPTO Patent for Alzheimer's Detection Kits
Summary
The USPTO has granted a patent (US12578344B2) to NEUROQUEST LTD. for compositions, kits, and methods for detecting preclinical Alzheimer's Disease. The patent covers binding agents for biomarkers such as CD163 and scavenger receptors, and methods for diagnosing AD and assessing therapeutic efficacy.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12578344B2 to NEUROQUEST LTD. This patent covers novel compositions, kits, and methods for the diagnosis and prognosis of Alzheimer's Disease (AD) in patients. The invention utilizes binding agents, such as monoclonal antibodies, that target specific biomarkers including CD163, CD91, CD59, MerTK, and other phagocytosis-related molecules. The patent also describes the use of panels of fluorophore-conjugated antibodies and methods for evaluating the efficacy of AD therapeutics.
While this is a patent grant and not a regulatory rule, it signifies a new intellectual property in the field of Alzheimer's diagnostics. Companies involved in developing diagnostic tools, therapeutic candidates for AD, or related research may need to be aware of this patent's claims to avoid potential infringement. The patent's claims focus on specific biomarkers and diagnostic methodologies, which could influence future research and development pathways in AD detection and treatment.
Archived snapshot
Mar 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions, kits, and methods for detecting preclinical alzheimer's disease
Grant US12578344B2 Kind: B2 Mar 17, 2026
Assignee
NEUROQUEST LTD.
Inventors
Xin Huang, Yihan Li, James Doecke, Baijun Gu, Michal Eisenbach-Schwartz
Abstract
Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
CPC Classifications
G01N 33/582 G01N 33/6896 G01N 2800/2821 C07K 16/2803 C07K 2317/30
Filing Date
2022-08-08
Application No.
17882671
Claims
24
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.